Related Experiment Video
Updated: Aug 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles
1Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Immunology, and Allergy, Boston, MA 02115, USA. panderson@rics.bwh
Abstract:
The beneficial effects of the anti-tumor necrosis factor (TNF) monoclonal antibodies infliximab and adalimumab and the soluble receptor fusion protein etanercept in the treatment of rheumatoid arthritis and a variety of other inflammatory disorders have been well described. However, less is known about the propensity of these agents to stimulate the production of antibodies against themselves and the clinical implications of such immunogenicity. A better understanding of the differential immunogenicity of these agents may help explain certain phenomena that have been reported with clinical use of anti-TNF agents (eg, infusion reactions [all agents], the need for increasing doses with prolonged use [infliximab]). This review will discuss our current understanding of the diverse immunogenic profiles of currently marketed anti-TNF agents.
Related Concept Videos
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Viral Protein Synthesis
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
